Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children < 3 Years of Age
10.1093/infdis/jiu359
Saved in:
Main Authors: | Nolan, Terry, Izurieta, Patricia, Lee, Bee-Wah, Chan, Poh Chong, Marshall, Helen, Booy, Robert, Drame, Mamadou, Vaughn, David W |
---|---|
Other Authors: | DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) |
Format: | Article |
Published: |
Oxford University Press (OUP)
2023
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/245327 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
by: Russell, F.M., et al.
Published: (2014) -
Hepatitis B vaccine boosters: Is there a clinical need in high endemicity populations?
by: John, T.J., et al.
Published: (2016) -
Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
by: Gillard, P, et al.
Published: (2020) -
Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
by: Goh, Yun Shan, et al.
Published: (2022) -
The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
by: Ho, Tzu-Chuan, et al.
Published: (2022)